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INTRODUCTION
Antimicrobials are valuable tools in the 
preservation of animal health and animal welfare, 
and must be cherished as they may save lives 
and prevent animal suffering (1). But the use of 
antimicrobial agents is the key risk factor for the 
development and spread of antimicrobial resistance 
(AMR). It is therefore generally recognized that 
data on the usage of antimicrobial agents in food-
producing animals (and companion animals) are 
essential for identifying and quantifying the risk of 
developing and spreading of AMR in the food-chain 
(2). The World Health Organization has indicated 
the follow up of antimicrobial resistance as one of 
the three top priorities (1). Antimicrobial resistance 
is deﬁ  ned as the ability of a microorganism to grow 
or survive in the presence of an antimicrobial at a 
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concentration that is usually sufﬁ   cient to inhibit 
or kill microorganisms of the same species. 
Antimicrobial consumption in animals selects for 
antimicrobial resistant bacteria in animals, leading 
to therapy failure of bacterial infections. Yet it might 
also endanger human health through either transfer 
of resistant bacteria or their resistance genes from 
animals to humans. The magnitude of this risk still 
needs to be quantiﬁ  ed while increasing evidence of 
resistance transfer between environments is found 
(1). This was also acknowledged by the European 
Council in 2008 through the Council Conclusions 
on Antimicrobial Resistance, which called upon 
the Member States to strengthen surveillance 
systems and improve data quality on antimicrobial 
resistance and on use of antimicrobial agents within 
both human and veterinary sectors (3). Having 
this in mind we decided to respond to the latest 
and to estimate the use of antimicrobial agents in 
veterinary sector in the Republic of Macedonia 
(RM) by analyzing the List of Registered Veterinary 
Medicinal Products (VMPs) and evaluating of the 
quality and practical use of this list according to the 6
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Anatomical Therapeutic Chemical System for the 
Classiﬁ  cation of Veterinary Medicines, with the aim 
of identifying the risk of development and spread of 
antimicrobial resistance.
ATCvet classiﬁ  cation system
To harmonize the veterinary antimicrobial 
agents to be included in the material, the Anatomical 
Therapeutic Chemical System for the Classiﬁ  cation 
of Veterinary Medicines (ATCvet) was applied. 
According to the WHO guidelines, the ATCvet 
is widely recognized as a classiﬁ  cation tool. This 
ATCvet Anatomical groups (1st level) ATC
QA Alimentary tract and metabolism A
QB Blood and blood forming organs B
QC Cardiovascular system C
QD Dermatologicals D
QG Genito-urinary system and sex hormones G
QH
Systemic hormonal preparations, excl. sex hormones and 
insulins  
H
QI Immunologicals -
QJ Anti-infectives for systemic use J
QL Antineoplastic and immunomodulating agents L
QM Musculo-skeletal system M
QN Nervous system N
QP Antiparasitic products, insecticides and repellents P
QR Respiratory system R
QS Sensory organs S
QV Various V
system is based on the same overall principles as the 
ATC system for substances used in human medicine 
(4). In most cases an ATC code exists which can be 
used to classify a product in the ATCvet system. The 
ATCvet code is created by placing the letter Q in front 
of the ATC code. In some cases, however, speciﬁ  c 
ATCvet codes are created, e.g. Immunologicals (QI) 
and Antibacterials for intramammary use (QJ51) (4). 
In both the ATC and the ATCvet systems, medicinal 
products are divided into groups, according to their 
therapeutic use (1st level) (see the Table below). 
Within most of the 1st level groups, medicinal 
products are subdivided into different therapeutic 
main groups (2nd level), coded for example as 
QA01, QA02, QA03 etc. Two levels of chemical/
therapeutic/pharmacological subgroups (3rd and 
4th levels), e.g. QA02A, QA02B etc. at the 3rd level 
and QA02AA, QA02AB etc at the 4th level, provide 
further subdivisions. At a 5th level, e.g. QA02AA01, 
chemical substances are classiﬁ  ed. This subdivision 
does not apply to QI – Immunologicals (4).
Distribution of veterinary medicines in RM
The  ﬁ   rst step in setting up surveillance of 
veterinary antimicrobial agents in some country is 
to identify and describe of the distribution system 
for veterinary antimicrobial agents (8). In our 
country, all VMPs containing antimicrobial agents 
are prescription-only medicines. This includes 
medicated premixes containing pharmaceutically 
active substances like antimicrobial agents. VMPs 
containing antimicrobial agents are provided 7
by Wholesaler Distributors (WD) to retailers 
of veterinary medicinal products (veterinary 
pharmacies) and veterinary organizations. 
Wholesaler-distributors obtain the VMPs from a 
wholesaler or from the Marketing Authorization 
Holder (MAH)/manufacturers. 
Antimicrobial VMPs are only available to 
animal owners/farmers by delivery from a pharmacy 
on veterinary prescription or directly from the 
veterinary organizations. Only veterinarians are 
entitled to sell VMPs to animal owners/farmers. 
Veterinarians have to conﬁ   rm the distribution of 
veterinary drugs to owners of food-producing 
animals if used for food production. Sales of VMPs 
by pharmacies account for a negligible amount of 
sales for farm animals. Medicated feeds have to be 
prescribed by veterinarians and manufactured either 
by authorized feed mills or by authorized farms. They 
are also may be imported to Macedonia. Medicated 
feeds containing antimicrobials are prepared from 
authorized premixes that are distributed through 
wholesaler-distributors. From feed mills, only 
farmers are receivers. Medicated feeds are used 
primarily for pig and poultry production.
Legal basis for the monitoring of sales of 
VMPs in RM
The collection of sales data by MAH/WDs is 
based on the national Law on veterinary medicinal 
products (Ofﬁ   cial Gazette of the Republic 
Macedonia No. 42/2010- article 37)(10). MAH/
WDs are obliged to keep records of all sales and to 
deliver these records (by template for the amount of 
sold out VMPs) to the Sector for Public Veterinary 
Health in Food and Veterinary Agency (FVA) on a 
yearly basis (11). The fact that many antimicrobial 
products are registered for use in different animal 
species and that there are currently no data available 
on the proportions of products used in the different 
species makes extrapolation up to animal species 
level unachievable at this very moment. The MAH 
of the products do provide estimated proportions to 
be included in the periodic safety update reports, yet 
these estimates are not always at hand, and are often 
based on limited data. For these reasons it was not 
feasible to use these data. 
MATERIALS AND METHODS
Data of all registered/renewed VMPs on the 
Macedonian market are collected from the web 
site of FVA (12), pharmaceutical companies 
(n=37) producing or importing VMPs and from 
MAH/WDs (n=16) that are assigned by the FVA 
to distribute them. The registered/renewed VMPs 
in last ﬁ   ve years in Macedonia are classiﬁ  ed 
according to composition of active component/s 
and main therapeutic indications regarding to the 
system of organs to which are intended to act on. An 
appropriate code from ATCvet Index 2013 provided 
from WHO Collaborating Centre for Drug Statistics 
Methodology at Norwegian Institute of Public 
Health (4) was designated to each VMP. On this 
way we have created a list of registered/renewed 
VMPs with appropriate ATCvet code and made a 
detailed analysis of the number of registered VMPs 
classiﬁ  ed by the system of organs and qualitative 
analysis of speciﬁ  c groups of VMPs. In particular, 
we analyzed groups of antimicrobial agents in 
different therapeutic main groups (see Table 3) in 
order to estimate the use of antimicrobial agents 
in veterinary sector in the RM and to identify the 
risk of developing and spreading of antimicrobial 
resistance. 
RESULTS AND DISCUSSION
 
In Macedonia, 318 VMPs were registered or 
renewed during the period from 01.01.2008 to 
31.12.2012. Figure 1 shows the number of registered/
renewed VMPs per year and manufacturers. All 
registered VMPs are from import, mainly from 
37 manufacturers from 16 European countries 
(Holland 18.2%, Serbia 17.0%, Croatia 15.0 %, 
Bulgaria 7.2 %, Slovenia 7.2 %). In the period of 
15 years, about 850 VMPs were registered/renewed 
or approximately 45 – 50 per year. In 2009 and 
2012, a little reduction in the number of registered/
renewed VMPs on the Macedonian market is 
observed, largely due to newly adopted legislation 
for registration and the impossibility of MAH/WD 
in quick time to adjust to the new regulations.  
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Table 1 shows the number of registered/renewed 
VMPs on the Macedonian market this moment 
according to their therapeutic use. The largest 
number of registered VMPs are from group QJ 
– Anti-infectives for systemic use (n = 93), while 
on the other hand there are no VMPs registered for 
primary therapeutic effect on cardiovascular system 
(group QC), for treatment of neoplasm (group QL- 
Figure 1. Number of registered/renewed VMPs in RM per year and manufacturers 
Antineoplastic and immunomodulating agents) and 
for treatment of diseases of eyes and ears (group 
QS - Sensory organs). Some of the anatomical 
groups like a group QB - Blood and blood forming 
organs, group QM - Musculo-skeletal system and 
group QR - Respiratory system were represented by 
insigniﬁ  cant number of VMPs. 
Anatomical groups (1st level) No. of VMPs
QA Alimentary tract and metabolism 38
QB Blood and blood forming organs 4
QC Cardiovascular system 0
QD Dermatologicals 9
QG Genito-urinary system and sex hormones 17
QH Systemic hormonal preparations, excl. sex hormones and insulins   13
QI Immunologicals 74
QJ Antiinfectives for systemic use 93
QL Antineoplastic and immunomodulating agents 0
QM Musculo-skeletal system 2
QN Nervous system 11
QP Antiparasitic products, insecticides and repellents 53
QR Respiratory system 2
QS Sensory organs 0
QV Various 2
                                                                                                        Total:    318
Table 1. Number of registered VMPs in RM according to their therapeutic use9
From the total number of the registered VMPs, 
pharmaceuticals are 76.7% (n=244) while immune-
preparations are 23.3% (n=74). The amount of 
antimicrobial agents and their combinations is 
32.7% (n=104), while the amount of antiparasitic 
is 16.7% (n=53). From the total number of 
registered immune-preparations greater number are 
vaccines for poultry and swines. In RM the use of 
antimicrobial agents is expanded, contrary to the 
immune-preparations. The above mentioned data are 
partly in coordination with the data for the registered 
VMPs in other European countries (5,6,7). Small 
market for speciﬁ  c VMPs results in lack of interest 
of the pharmaceutical companies to register VMPs 
with low or no commercial value, creating serious 
problem for the veterinary practitioners. Table 2 
provides an overview of the number of registered/
renewed antimicrobial pharmaceuticals and the 
number of antimicrobial medicated premixes per 
year on the Macedonian market for the period 2008 
- 2012. 
Table 2. Overview of the number of registered/renewed a    ntimicrobial products on the Macedonian 
market in period 2008 - 2012
2008 2009 2010 2011 2012
Number of antimicrobial pharmaceuticals   1 8 8 3 01 71 5
Number of antimicrobial medicated premixes   72421
Total number of registered/renewed 
antimicrobial products on the market  25 10 34 19 16
In the period of 5 years, 104 antimicrobial 
products were registered and renewed or 
approximately 20 per year. In RM the use of 
parenteral forms of antimicrobial products (inj. 
sol.; inj. susp.) is expanded 51% (n=53), contrary 
to antimicrobial medicated premixes 15.4% (n=16). 
The amount of intramammary products is 6.73% 
(n=7), while the amount of intrauterine products is 
2.9% (n=3). With exception of macrolide antibiotics 
tulathromycin and tilmicosin (since 2009 and 
2012) and third generation cephalosporin ceftiofur 
(since 2009), no additional active substances were 
registered on the market in the reported years. Thus 
the observed number in available products is largely 
due to the marketing of new formulations or new 
generic products based on existing active substances. 
Table 3 provides an overview of the number of 
antimicrobial agents from different therapeutic 
main groups available on the Macedonian market 
this moment.
Table 3. Groups of antimicrobial agents and corresponding ATCvet codes available on the Macedonian 
market this moment
Groups of antimicrobial agents  ATCvet codes  Total
Antimicrobial agents for intestinal use  QA07AA; QA07AB  4
Antimicrobial agents for dermatological use  QD06AA; 
QD06BA  4
Antimicrobial agents for intrauterine use  QG51AA; QG51AC; QG51AE; QG51AX 
QG51BA; QG51BC; QG51BE  3
Antimicrobial agents for systemic use  QJ01 86
Antimicrobial agents for intramammary use  QJ51 7
Antimicrobial agents for use in sensory organs 
QS01AA; QS01AB 
QS02AA 
QS03AA 
0
Antimicrobial agents for use as antiparasitic  QP51AG 0
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Antimicrobial products which are used as 
antiparasitic agents (group QP51AG) and for use 
in sensory organs were not registered. Some group 
of the antimicrobial agents like a group QA07 
– Antibacterials for intestinal use, group QD06 - 
Antimicrobial agents for dermatological use, group 
QG51- Antibacterials for intrauterine use and group 
QJ51 - Antibacterials for intramammary use were 
represented by insigniﬁ  cant number of VMPs. The 
ATCvet codes (ATC level 3 or 4) included in each 
antimicrobial class are listed in Table 4.
Table 4. ATCvet codes included in the different classes of antimicrobials
Tetracyclines (n=25), penicillins (n=27) and 
quinolones (n=13) are the top three antimicrobial 
classes, comprising approximately 62.5 % of 
all registered antimicrobial agents. Generally, 
tetracyclines and/or penicillins accounted for the 
highest proportion of the use in the reporting period. 
For antimicrobial agents considered to be critically 
important antimicrobials in human medicine, such 
as the 3rd and 4th-generation cephalosporins, 
Class of antimicrobials  ATCvet codes included  Total
Aminoglycosides  QA07AA01 (1)
QJ01GA01 (1), GB03 (1), GB04 (1)  4
Cephalosporins 
QG51AA05 (1)
QJ01DA90 (3); DB01 (1) 
QJ51DA01 (1) 6
Amphenicols  QJ01BA52 (1); BA90 (3)   4
Macrolides  QJ01FA90 (1), FA91 (1), FA94 (1) 
  3
Penicillins  QJ01CA04 (5); CE30 (4); CR02 (3)   
QJ51RC (1) 13
Polymyxins  QA07AA10 (1)  1
Quinolones  QJ01MA90 (12) 
QJ01MB07 (1)  13
Sulfonamides and 
trimethoprim 
QA07AB (2)
QJ01EQ (4); EW (6)    12
Tetracyclines 
QD06AA  (3)
QD07C     (1)
QG51AA01 (1); AA08 (1)
QJ01AA02 (1), AA03 (2); AA06(9)  18
Pleuromutilins   QJ01XQ01 (7)  7
Combinations of 
antibacterials
QJ01RA01(penicillins)/QJ01RA95(polymyxins)(1)
QJ01RA01(penicillins)/QJ01RA97(aminoglycosides) (8)
QJ01RA02 (sulfonamides)/QJ01RA90(tetracyclines) (1)
QJ01RA02/QJ01RA90/QJ01RA97 (2)
QJ01RA90 (tetracyclines + tiamulin) (3)
QJ01RA94 (lincosamides + spectinomycin) (1)
QJ01RV01 (penicillin+polymyxin+corticosteroid) (1)
                   (penicillin+aminoglycos+corticosteroid) (1)
QJ51RC23 (penicillin+aminoglycosides) (2)
QJ51RV01 (cephalosporin+corticosteroid) (1)
               (penicillin+aminoglycosides+ corticosteroid)(1)
 tetracyclin+aminoglycosid+bacitracin+corticosteroid)(1)
23
macrolides and the ﬂ   uoroquinolones, an overall 
increase in usage is observed. These classes of 
compounds are used for food producing animals 
and could potentially inﬂ  uence the prevalence of 
resistance. 3rd and 4th-generation cephalosporins 
and ﬂ  uoroquinolones are considered as particularly 
important in human medicine because they are 
among the only alternatives for the treatment of 
certain infectious diseases in humans. Measures to 
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counter a further increase and spread of resistance in 
animals should therefore be considered.
Although there is a legal basis for the collection 
of sales data on VMPs on an annual basis from 
MAH/WDs to the FVA in this moment the data is 
not available to us. It should be emphasized that 
sales of antimicrobial agents (mg per population 
correction factor - PCU) are not indicators for the 
level of exposure (9). The main goal of calculating 
the amount of antimicrobial agents is to adjust trends 
in the use within a country for possible changes in 
the size of animal livestock population and number 
of slaughtered animals (7). Also, the sales data on 
veterinary antimicrobial agents cover all species, 
while the population correction factor does not 
include companion animals or minor species. 
 
DISCUSSION 
The use of antimicrobial agents is an important 
risk factor for the development of antimicrobial 
resistance. Monitoring of use of antimicrobials is 
one of the important sources of information used for 
the assessment and management of risks related to 
antimicrobial resistance. Our work provides the ﬁ  rst 
data on the usage of antimicrobial drugs in animals 
in Macedonia for the given period and shows a high 
usage of antimicrobials in veterinary sector. Many 
European countries have been reporting these already 
for several years. Moreover it has recently become a 
European engagement from member states to report 
on the level of antimicrobial consumption in animal 
production (7). Also in the context of methicillin 
resistant Staphylococcus aureus, extended spectrum 
beta-lactamase, and other emerging resistance traits, 
comparable and evolutionary data on antimicrobial 
consumption are needed. This work can thus also be 
seen as a starting point for continuous monitoring of 
using the antimicrobial agents in future. The reported 
table will also be used as a reference for comparison 
and to evaluate effects of policy measures. 
As the data presented in this work are aggregated 
per antimicrobial class, they do not allow for more 
in-depth analysis. The types and incidences of 
infectious diseases vary considerably between 
animal species and production category (e.g. veal 
versus dairy cattle), and consequently the sales 
of veterinary antibacterial agents are thought to 
be inﬂ   uenced by animal species demographics. 
To identify the factors underlying the differences 
observed, there is a need for detailed sales data of 
each antimicrobial VMPs. As a ﬁ  rst step, the use of 
the standardized ESVAC template for the collection 
of data (9) will provide detailed data at package 
level, including information on administration form 
and herd treatment versus individual treatment, 
allowing for more detailed analysis than can be 
done using the aggregated data. As some agents are 
administered in much higher dosages than others 
(e.g. tetracyclines versus cephalosporins), there is a 
need to continue to reﬁ  ne the tools for analyzing the 
data on sales of antimicrobial agents. The next steps 
should be to analyze the data taking into account 
variance in the dosing and the treatment duration of 
each antimicrobial VMPs. 
CONCLUSIONS
The extended and uncontrolled use of 
antimicrobial agents in Macedonia is representing 
the main risk factor for the development of 
antimicrobial resistance. Data on the usage of 
antimicrobial agents particularly in food producing 
animals is essential for identifying and quantifying 
this risk in the food-chain. The ATCvet classiﬁ  cation 
gives a detailed view on the real quantity of the 
different classes of registered VMPs. It is practical 
tool for identiﬁ  cation of different groups of VMPs 
for the veterinary practitioners as well as all subjects 
involved in production, trade and distribution of 
VMPs. The results obtained given an overall picture 
of trends in the use of veterinary antimicrobial 
agents in R. Macedonia. Currently data indicate a 
high use of antimicrobials indicating that this class 
of VMP should be monitored closely to avoid the 
appearance of antimicrobial resistance and possible 
consequences for animal and human health. 
Nevertheless, such data should be interpreted with 
caution, with further analysis to assess exposure 
trends and the effect of policy measures for prudent 
use.
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